Coverage summary
| Indication | Coverage |
|---|---|
| Wegovy (weight loss) | No |
| Zepbound (weight loss) | Limited |
| Ozempic or Mounjaro (type 2 diabetes) | Yes |
If Connecticut Medicaid says no, two cash programs to check.
No insurance needed.
- Strut Health$149 a month, with auto-refillcompounded semaglutideCheck price →You pick Weight Loss, then a five-minute online visit
- Shed$199 a month30% off first month with code Shed10compounded semaglutideCheck price →A health form first, then you choose your plan
Cheapest GLP-1 without insurance compares the three cash routes, and cheapest GLP-1 in Connecticut prices each drug that ships there.
A clinical trial costs nothing, and nobody checks your income.
Prior-authorization criteria
These rules come from the state preferred drug list (PDL), the list of drugs Connecticut Medicaid has agreed to pay for. Prior authorization means your doctor asks the plan to approve the drug before the pharmacy fills it. Nearly every state covers the diabetes path that way.
| Criterion | Value |
|---|---|
| How hard the approval is | Medium |
| BMI threshold (weight-loss path) | The state does not publish one. Ask your plan. |
| Comorbidity required | No |
| Last PDL update reviewed | December 2025 |
If the plan denies it, the appeal letter templates cover the reasons plans give and what to send back.
What HUSKY Health paid for GLP-1s
HUSKY Health reported 31,955 GLP-1 prescriptions to CMS in 2025's last quarter and paid pharmacies $38.8 million.
Counts Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda and Rybelsus, in fee-for-service and managed care, before rebates. CMS blanks its smallest rows, so the real figures are higher. Source: CMS State Drug Utilization Data.
What this means in practice
Connecticut Medicaid (HUSKY Health) does not cover GLP-1s for weight loss on its own. It does cover them for four other reasons. Wegovy is covered to cut heart attack and stroke risk, and for MASH, a fatty liver disease. Zepbound is covered for moderate to severe sleep apnea, which means your sleep study scored 15 or higher and you are already on a CPAP machine. That one has been in place since July 1, 2025. Type 2 diabetes is the fourth route. All four need your doctor to get approval first. That is the prior authorization step.
Managed-care organizations in Connecticut
Connecticut Medicaid operates primarily as fee-for-service. PA submissions go directly to the state Medicaid pharmacy benefit administrator rather than to a contracted managed-care organization (MCO), the kind of private health plan that runs Medicaid coverage in most states.
Cash-pay alternatives if Medicaid does not cover you
Connecticut's Medicaid weight-loss drug benefit covers orlistat, Xenical and phentermine at a BMI above 40, or above 35 with a diagnosed comorbid condition. No GLP-1 is on that list. Type 2 diabetes on your chart still opens the diabetes route.
If you end up paying cash, the GLP-1 cost guide has what each cash route costs, from the compounded floor to the manufacturer-direct brand prices. Federal law bars manufacturer savings cards for anyone on Medicaid.
If a supply gap rather than cost is blocking your refill, the GLP-1 shortage tracker shows which formulations the FDA lists as in shortage now. And if you are 65 or older and also have Medicare, the senior GLP-1 hub lays out the Medicare coverage paths for dual-eligible patients.
For the full cash-pay picture specific to Connecticut, see the cheapest GLP-1 in Connecticut guide.
13 GLP-1 clinical trials are recruiting in Connecticut, and a study supplies its own study medication. Every site is listed on GLP-1 clinical trials in Connecticut.
Connecticut Medicaid GLP-1 FAQ
Does HUSKY Health (Connecticut Medicaid) cover Wegovy for weight loss?
Does HUSKY Health (Connecticut Medicaid) cover Zepbound for weight loss?
Does HUSKY Health (Connecticut Medicaid) cover Ozempic or Mounjaro for diabetes?
What if HUSKY Health (Connecticut Medicaid) does not cover my GLP-1?
Other state Medicaid pages
See the full 51-state coverage table for the side-by-side view across every US state.
How we built this page
Compiled from each state Medicaid's published preferred drug list, PA criteria and PDL committee minutes. State Medicaid programs are not federally required to cover obesity drugs; the diabetes indication is covered nearly everywhere with PA. State-level data is point-in-time and shifts each PDL cycle. Always verify with your state Medicaid plan before relying on this page.
Checked August 24, 2026. We check each state Medicaid PDL and PA criteria quarterly. If you have recently had a different experience with Connecticut Medicaid, email hello@glpchart.com with the details and we will check it.